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Abstract
Objectives—To investigate the histological spectrum of nonalcoholic fatty liver disease
(NAFLD) in children with normal, mildly elevated (26–50 U/L boys, 23–44 U/L girls), or elevated
(> 50 boys, > 44 girls) serum alanine aminotransferase (ALT) levels.
Study design—The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
enrolls children 5–18 years with NAFLD. We analyzed baseline clinical and histological data
from 91 children with suspected NAFLD and normal or mildly elevated ALT and liver biopsy
within 180 days of ALT, and compared them with 392 children with elevated ALT.
Results—Of 91 children, 17 (19%) had normal and 74 (81%) had mildly elevated ALT levels.
Overall, 45% of biopsies had ≥ 33% steatosis, lobular inflammation grade was ≥ 2 in 22%, 81%
had portal inflammation, 29% had ballooned hepatocytes, 35% had “suspicious/borderline”
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steatohepatitis, and 8% had definite NASH, 34% had NAFLD activity score (NAS) ≥ 4. Overall,
46% had fibrosis (38% mild/moderate and 8% bridging/cirrhosis). Marked steatosis (50% vs 24%)
and fibrosis (54% vs 12%) were significantly more common in mildly elevated vs normal, with no
difference in ballooning, inflammation, or NAS ≥ 4. Fibrosis stage 3/4 was seen in none of the
children with normal ALT, and in 9% of the mildly elevated and 15% of the elevated.
Conclusions—Liver biopsies of children with NAFLD with normal or mildly elevated ALT
levels show significant histologic abnormalities, including advanced fibrosis in children with
mildly elevated ALT. ALT thus may underestimate liver injury in NAFLD. Appropriate ALT cut-
off levels can help identify children at risk for more severe disease.
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Nonalcoholic fatty liver disease; alanine aminotransferase; liver histology; children; obesity
Nonalcoholic fatty liver disease (NAFLD) is one of the most common co-morbidities of
pediatric obesity. Nonalcoholic steatohepatitis (NASH) can result in cirrhosis, even in
childhood.1, 2, 3 The American Academy of Pediatrics Guidelines recommend biannual use
of serum alanine aminotransferase (ALT) to screen overweight and obese children for
NAFLD.4 Elevations in liver enzymes in these children are common.5 Data are limited
concerning appropriate aminotransferase cut-offs to identify obese children with potential
for NASH.
Upper limit of normal (ULN) ALT values used in US children’s hospitals vary widely and
lack sensitivity to detect NAFLD in children. The median ULN of ALT nationally is 53 U/L
and ranges from 30–90 U/L.6 Recently, new evidence-based standards for normal ALT in
children were proposed--≤ 25 U/L for boys and ≤ 22 U/L for girls--when NHANES III data
were analyzed including only children who had no risk factors for underlying liver disease.6.
The NIDDK NASH Clinical Research Network (CRN) maintains a large prospective
database of clinical information on children with fatty liver.7 We evaluated clinical and
histologic variables in children with normal ALT or mildly elevated ALT levels to
determine the spectrum of histologic abnormalities and assess the usefulness of ALT in
identifying active liver disease. A comparison group of children with elevated ALT levels
was examined.
Methods
The pediatric NAFLD studies were designed by subcommittees of the NASH CRN Steering
Committee, the latter composed of principal investigators from each clinical site, the two co-
chairs of the Pathology Committee, the principal investigator from the Data Coordinating
Center (DCC), and the NIDDK scientific officer [all listed in the appendix]. After approval
by the Steering Committee, studies were approved by the Institutional Review Boards at
each site. Enrolled patients and their guardians gave written informed assent and consent.
The protocols, assent/consent forms, and manual of operations were approved by a Data and
Safety Monitoring Board established by the NIDDK specifically for the NASH CRN. All
studies were in compliance with Good Clinical Practice Guidelines for Human Research
Quality Standards.
Children 5 through 18 years of age with definite or suspected NAFLD meeting eligibility
criteria, were enrolled into the NIDDK NASH CRN Database or Database 2, which are
observational studies conducted at 12 U.S. medical centers8 For the initial database study,
inclusion criteria defined NAFLD as suggestive radiographic study or local liver biopsy
evidence of NAFLD. After 2010 (Pediatric NAFLD Database 2 study), only children who
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had been previously enrolled or had undergone standard-of-care liver biopsy within the 3
months prior to enrollment were eligible. Children were excluded from NASH CRN studies
if they had history of alcohol consumption; evidence of other forms of chronic liver disease;
history of medicines known to cause fatty liver; history of total parenteral nutrition;
biliopancreatic diversion or bariatric surgery; short bowel syndrome; suspected or confirmed
hepatocellular carcinoma; known HIV positivity; conditions that were likely to interfere
with study follow-up; or inability to provide informed consent. Comprehensive data,
including demographics, anthropometrics, medical history, and routine laboratory studies
were collected on all patients at entry.
Data included in this analysis were from children enrolled between 2004 and January 2013
in either phase of the NAFLD Database who had histology data from a centrally reviewed
biopsy obtained within 6 months of baseline ALT measurement, and whose ALT value close
to biopsy was normal (≤ 25 U/L for boys and ≤ 22 U/L for girls) or mildly elevated (26–50
U/L or less for boys and 23–44 U/L or less for girls). A comparison group consisted of
children with elevated ALT (> 50 U/L for boys or > 44 U/L for girls) and who had had a
liver biopsy..
Sample Analyses
Routine laboratory studies were performed on fresh samples in CLIA certified laboratories
at each clinical site according to standard clinical protocols. Liver biopsy specimens were
formalin fixed, paraffin embedded and unstained slides were sent to the DCC for inclusion
in a central pathology repository. Hematoxylin and eosin (HE), Masson’s trichrome and
Perls’ iron stains were prepared and reviewed centrally by the NASH CRN Pathology
Committee, a group of 9 hepatopathologists who were masked to clinical data. Biopsies
were scored by consensus during Pathology Committee Meetings using the NAFLD Activity
Score (NAS) and fibrosis stage.9 The NASH CRN Pathology Committee designed and
validated a histological feature scoring system that addresses the full spectrum of lesions of
NAFLD for use in clinical trials. The scoring system comprised 14 histological features, 4 of
which were evaluated semiquantitatively: steatosis (0–3), lobular inflammation (0–3),
hepatocellular ballooning (0–2), fibrosis (0–4) and other features were recorded as present or
absent. Diagnoses are also rendered: definite steatohepatitis, borderline 1a or 1b
(centrilobular accentuation or portal accentuation, respectively) and definitely not
steatohepatitis. The NAS was determined by summing the unweighted scores for steatosis,
lobular inflammation and hepatocellular ballooning (0–8).
Data Analyses
Cross-sectional analyses of demographic factors including sex, age, race (white vs non-
white) and ethnicity; anthropometrics including Tanner stage (stage 1 vs other), body mass
index (BMI) z score; and the history of co-morbid conditions including diabetes,
hyperlipidemia, and hypertension (reported diagnosis or on current treatment) were
performed. We also examined serum levels of aspartate aminotransferase (AST), gamma
glutamyl transpeptidase (GGT), triglycerides, total cholesterol, HDL and LDL cholesterol,
hemoglobin A1c (HbA1c), fasting glucose and insulin as well as the homeostasis model
assessment (HOMA) index. Histological features analyzed included the fibrosis stage (none,
mild/moderate (1–2), bridging/cirrhosis (3–4), NAS, presence of definite or borderline
NASH, steatosis grade, lobular inflammation (< 2, ≥ 2), portal inflammation (none, mild or
more), hepatocellular ballooning (none, few to many), acidophil bodies (rare/absent, many).
Data are reported as means and standard deviations or percents. The significance of
differences between the groups were assessed using either Fisher exact test for 2×2
categorical variables, Cochran-Armitage exact trend test for 2×3 categorical variables, or
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Kruskal-Wallis test for continuous variables.10 All analyses were conducted using SAS
9.311 and Stata (version 12) softwares.12 Nominal, two-sided P values were presented.
Results
Of 483 children ages 5–18 enrolled in the NASH CRN database study from October 2004
until January 2013, 91 children had normal or mildly elevated ALT with a centrally
reviewed liver biopsy within 180 days of baseline ALT measure; 32 (35%) were enrolled in
NAFLD Database and 59 (65%) in NAFLD Pediatric Database 2 Study. Among the elevated
comparison group consisting of 392 children, 11% were enrolled in NAFLD Database, 46%
in NAFLD Pediatric Database 2, and 43% in a treatment trial.
The reasons for NAFLD evaluation reported by parent at entry interview in the normal or
mildly elevated subjects included: symptoms of liver disease (22%), results of evaluation for
other illness (38%), during routine physical exam (41%), blood donation (2%), other (4%).
By history, data that supported the first diagnosis of NAFLD in children included: elevated
ALT (74%), liver biopsy (53%), and radiographic evidence of steatosis (55%). Children
were predominantly male, Caucasian, and Hispanic. Mean age of the children with normal
or mildly elevated ALT was 12.9 ± 2.8 years and three-quarters were pubescent; 69% were
moderately to severely obese, with BMI Z score ≥ 2. Mean HOMA-IR was 6.3 ± 4.5, with
relatively normal mean cholesterol and triglycerides; 10% of the children with normal or
mildly elevated ALT had been diagnosed with diabetes, 8% with hyperlipidemia, and 7%
percent with hypertension (Table I; available at www.jpeds.com).
Liver biopsies were obtained within an average of 58 days (range 5 to 154) of blood
collection for ALT determination at enrollment for the normal group and 47 days (0–175) of
enrollment ALT for the mildly elevated group. Regression analysis (not shown) showed no
interaction effects between interval from ALT to biopsy and ALT group. In these children
with normal or mildly elevated ALT, steatosis was more than grade 2 (> 33%) in 45%
(Table I). Lobular inflammation grade was 2 or more in 22%, and 81% had some degree of
portal inflammation. Ballooning was seen in 29% and many acidophil bodies were present
in 29%. Fibrosis was present in almost half of the biopsies and was distributed as stage 1 or
2 fibrosis (38%) and bridging fibrosis or cirrhosis (8%). The diagnosis of steatohepatitis was
borderline in 35% and definite in 8% (distribution among ALT groups shown in Figure 1).
A NAS of 4 or more was seen in 34% (Table I).
Subgroup analysis comparing children with normal ALT and those with mildly elevated
ALT is shown in Table I. Children with mildly elevated ALT were younger than those with
normal ALT but had higher BMI Z-score. Both AST and GGT were significantly lower in
the normal group. HOMA-IR did not differ between these groups. Steatosis grade was
significantly lower in the normal ALT group: greater than 33% steatosis was seen in 24% of
the normal group compared with 50% of the mildly elevated group (p=0.02). Fibrosis, seen
in 54% of the mildly elevated group, was significantly (p<0.003) more frequent than in
normal group (12%) (Figure 2). In the normal group, two biopsies showed periportal fibrosis
(stage 1c), but there was no child with advanced fibrosis. Notably, there were no significant
differences between groups in the rates or distribution of inflammation, ballooning,
steatohepatitis diagnosis, or NAFLD activity score < 4 vs. ≥ 4. However, the mildly elevated
group compared with the normal ALT group contained fewer children with "no NASH" and
all of the children with the diagnostic category of "definite" NASH (p=0.61)
Comparison of the mildly elevated vs elevated ALT groups is shown in Table II. Mean ALT
for elevated was 123.1 and for mildly elevated was 37.4. Significant findings included
higher AST (mean 71.9 vs 31.6), GGT (mean 50.7 vs 29.8), percent with moderate/severe
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steatosis (74% vs 50%), lobular inflammation ≥ grade 2 (48% vs 20%), ballooning (48% vs
31%), bridging fibrosis/cirrhosis (15% vs 9%), definite NASH (30% vs 9%), and high NAS
(72% vs 36%) in those with elevated liver enzymes compared with those with mildly
elevated liver enzymes (Figure 2).
Advanced Fibrosis
The 7 children with advanced fibrosis (stages 3 or 4) and mildly elevated ALT were all
male, younger (average age 12 ± 3 years), mostly Hispanic (5 of 7), obese (average BMI Z
score 2.46 ± 0.55), and insulin-resistant (HOMA 5.32 ± 3.09). None had ever been
diagnosed with diabetes, hypertension, or hyperlipidemia. Only one of these children had
fluctuating ALT subsequent to the study value (data not shown). Most biopsies with
advanced fibrosis did not have a high NAS score: 6 of the 7 had a NAS score of 4 or less.
Ballooning was only seen in 29% but all had at least mild portal inflammation. Four were
diagnosed as borderline steatohepatitis and 3 were diagnosed as “not steatohepatitis”.
Fibrosis stage was 3 in all but one, who had cirrhosis, stage 4 (Table III; available at
www.jpeds.com).
Discussion
NAFLD is the most common chronic liver disease in pediatrics, occurring in 9.6% of
children and as many as 38% of obese children.3, 13 Liver disease can range from isolated
hepatic steatosis to steatohepatitis with active inflammation to cirrhosis.9.. Ultrasound is
often used as a noninvasive means to screen for steatosis; it has only a moderate positive
predictive value, does not detect all cases, and reflects fat and sometimes fibrosis, but not
inflammation or injury.14 Serum ALT levels, a surrogate for necroinflammatory activity, is
sometimes used as a proxy for disease activity. Biannual screening of obese children for
ALT has been recommended by an expert panel with representatives from 15 different
societies including the American Academy of Pediatrics, overseen by the Center for Disease
Control (CDC) and Maternal and Child Health Branch of HRSA. Evidence as to the utility
and cost-effectiveness of this approach is still lacking and such a recommendation to
monitor ALT in obese children was not made in the recent American Association for the
Study of Liver Diseases NAFLD Management Guidelines.15 Furthermore, appropriate ALT
criteria for referral (the expert committee recommended “twice ULN”), biopsy, or more
aggressive interventions have not been established. Using ultrasound as a standard, the
sensitivity of using ALT >30 or 40 U/L as a cut-off for identifying NAFLD is poor.16. Liver
biopsy is the clinical standard for semi-quantitatively evaluating fat, hepatocellular injury,
and evaluation of fibrosis. However, the decision of whether or not to perform a liver biopsy
is challenging and includes the consideration of cost and risk.17
The average ULN ALT in pediatric hospitals in the United States is 53 U/L.6 A recent report
demonstrated, by excluding children with obesity, viral hepatitis, history of potentially
hepatotoxic medications, and other potential causes of liver injury, that the 95th percentile
ULN ALT for girls is 22 U/L and for boys is 25 U/L. Using a cut-off of 50 U/L for boys and
44 U/L for girls, twice the suggested ULN, we analyzed the degrees of steatosis,
inflammation, hepatocyte injury, and fibrosis in 91 children with prospectively assessed data
and blinded pathology review from the NASH CRN. We demonstrated the presence of
considerable inflammation, ballooning, acidophil bodies and fibrosis in children with
NAFLD and stringently defined normal or mildly elevated ALT.
Biopsies in children with normal ALT were noted to have definite histologic abnormalities,
but not important fibrosis. Even among children with normal ALT (half of whom had BMI
Z score < 2), 24% had NAS scores in the 4–8 range and almost 30% had borderline NASH;
the degree of steatosis in these children was less than those with higher ALT, however, and
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only 2 of 17 biopsies had any fibrosis (mild to moderate). Biopsies in those subjects with
mildly elevated ALT demonstrated significantly more steatosis and fibrosis than the normal
group and included 7 children with advanced fibrosis (stages 3–4). Inflammation,
ballooning, or rate of NAS > 4 were not greater in this mildly elevated group, which
contained children who were younger but heavier than those in the normal group. Most of
the children with mildly elevated ALT and advanced fibrosis did not have NAS > 4. They
thus did not fulfill the typical criteria for NASH, reinforcing the idea that pediatric NASH is
a heterogeneous disorder and that histologic activity of NASH may decrease as fibrosis and
architectural remodeling increase. Even more notable histologic abnormalities and
significantly more fibrosis were seen in the elevated ALT comparison group. Overall,
histological abnormalities occurred in all ALT groups, including those previously
considered by many as normal.
In a retrospective single-center report on 106 children with NAFLD, A-Kader et al reported
fibrosis in 10 of 15 children with normal ALT (31 ± 1.6 IU/L); 2 children had stage 2
(central and portal) or 3 (bridging) fibrosis.18 Manco et al showed no difference in mean
ALT levels in children with NAS < 2, 3–4, or > 5.19 They reported steatosis grade 2–3,
necroinflammatory grade 2–3, and fibrosis stage 2–4 in 68.1%, 4.7%, and 81.4%,
respectively (fibrosis stage was 3 or 4 in 11.6%) in a sample of 43 children with “normal
ALT” (not defined)20 In a previous report from the NASH CRN in a prospectively studied
group of 176 children (with mean ALT of 90), ALT increased with higher NAS: mean ALT
was 74 with NAS 1–3, 87 with NAS 4–5, and 114 with NAS 6–7 (P-trend < 0.001). The
area under the ROC curve for ALT comparing none/mild fibrosis vs moderate fibrosis was
0.62.2.
Biopsy data in adults with low ALT are available. Fracanzani reported results of 4 adult
NASH databases in Italy, finding NASH in 59% of adult patients with ALT < 40 U/L.21
Mofrad et al described the clinical and histologic spectrum of NAFLD;. of 51 adults with
normal ALT (defined as ALT < 75 U/L), 12 had bridging fibrosis and 6 had cirrhosis22.
Although steatosis and fibrosis were less in 15 subjects whose ALT was below 30 U/L, the
prevalence of advanced fibrosis was similar in both groups.
The strengths of our study include prospective evaluation of a large and well-characterized
multicenter population of children with NAFLD and low or mildly elevated ALT. Biopsies
were assessed by pathologists blinded to age and all clinical information at the time of
review using a structured and validated scoring system. Several weaknesses are inherent.
We studied a selected population of children who underwent biopsy for evaluation of
NAFLD; indications for this standard-of-care biopsy varied, making generalizability of these
data to the general population unclear. Furthermore, we evaluated only one ALT
measurement, the one closest to biopsy; some subjects had a prior history of elevated ALT
leading to initial evaluation for NAFLD. Although on average biopsy was done within a
clinically realistic 47–58 days of ALT determination, biopsies up to 176 days from ALT
were included. Our regression analysis, however, showed no significant interactions
between timing of biopsy and ALT group. It is conceivable that the disease process could
have evolved during that time interval, perhaps associated with weight changes. We cannot
exclude previous or subsequent fluctuations of ALT in these subjects. Factors such as BMI,
recent diet, time of day, race, ethnicity, and storage conditions can influence ALT.23 Few of
the children enrolled in the NASH CRN Database studies had ALT values < 50 U/L for boys
and < 44 U/L for girls; therefore, the numbers available for multivariable analyses
comparing the 2 groups and controlling for some of these factors were inadequate.
NASH is a serious cause of liver disease in children. The fact that diabetes (10%),
hyperlipidemia (8%), and hypertension (7%) are so common in children with normal or
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mildly elevated ALT in this study underscores the metabolic impact of obesity in this group.
This study shows that important histologic abnormalities can occur in this group, and
implies that they might progress, unheralded by liver enzyme abnormalities, to more
advanced liver disease over time. Children with fatty liver who have mildly elevated ALT
may have that level reported as normal by many labs, yet may have significant liver disease.
Even when stringently defined, normal ALT does not signify lack of liver injury in children
with fatty liver; clinicians should be aware that serious liver disease may be present in these
children. Liver biopsy has a key role in the evaluation of children with NAFLD as histology
remains the gold standard for the assessment of NAFLD. The development of more
informative noninvasive biomarkers for NAFLD activity and fibrosis is crucial in children
as well as in adults.
Supplementary Material
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University School of Medicine, Indianapolis, IN: Elizabeth Byam, RN; Oscar W.
Cummings, MD; Ann Klipsch, RN; Jean P. Molleston, MD; Girish Subbarao, MD; Johns
Hopkins Hospital, Baltimore, MD: Caroline Devadason; Kimberly Pfeifer, RN; Ann
Scheimann, MD; Michael Torbenson, MD; Mount Sinai Kravis Children’s Hospital, New
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Figure 1.
Percent of children in each NASH diagnosis category for normal, mildly elevated, and
elevated ALT. NASH diagnosis categories are NAFLD/no NASH, Borderline Zone 3 (1a),
Borderline Zone 1 (1b), Definite (2).
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Figure 2.
Percent of biopsies in fibrosis stages None, Mild, Moderate, and Advanced for each ALT
group.
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Table I
Baseline Demographic, Clinical and Histologic Characteristics of Children with NAFLD Comparing Normal
and Mildly Elevated Levels of Alanine Aminotransferase (ALT)
ALT level (U/L)
Total*
(N=91)
Normal
(N=17)
Mildly
Elevated
(N=74) P†
Demographics:
  Male, N (%) 60 (66%) 13 (76%) 47 (64%) 0.31
  Age at enrollment (years), mean ± SD [range] 12.9 ± 2.5 [7, 18] 14.1 ± 2.4 [9, 17] 12.6 ± 2.5 [7, 18] 0.03
  Caucasian, N (%) 69 (76%) 15 (88%) 54 (73%) 0.23
  Hispanic, N (%) 59 (66%) 14 (82%) 45 (62%) 0.11
Anthropometric:
  Tanner stage 1, N (%) 19 (21%) 2 (12%) 17 (23%) 0.02
    Stage 2–3 53 (58%) 7 (41%) 46 (62%)
    Stage 4–5 19 (21%) 8 (47%) 11 (15%)
  Body Mass Index (Z-score), N (%): 0.02
    < 2.0 (overweight or less) 28 (31%) 9 (53%) 19 (26%)
    2.0 – (moderately obese) 41 (45%) 6 (35%) 35 (47%)
    2.5 or more (severely obese) 22 (24%) 2 (12%) 20 (27%)
Co-morbidities (diagnosis and/or treatment):
  Diabetes, N (%) 9 (10%) 1 (6%) 8 (11%) 1.00
  Hyperlipidemia, N (%) 7 (8%) 0 (0%) 7 (9%) 0.34
  High Blood Pressure, N (%) 6 (7%) 1 (6%) 5 (7%) 1.00
Laboratory values, mean ± SD:
  Liver panel and platelets:
    ALT (U/L) 34.3 ± 9.1 20.7 ± 2.9 37.4 ± 6.8 <0.0001
    AST (U/L) 30.0 ± 8.3 22.9 ± 6.9 31.6 ± 7.8 0.0001
    GGT (U/L) 28.5 ± 20.5 22.9 ± 21.5 29.8 ± 20.2 0.002
    Creatinine (mg/dL) 0.60 ± 0.15 0.66 ± 0.16 0.58 ± 0.14 0.04
    Bilirubin, direct (mg/dL) 0.10 ± 0.06 0.12 ± 0.06 0.09 ± 0.05 0.10
    Albumin (g/dL) 4.4 ± 0.4 4.5 ± 0.2 4.4 ± 0.4 0.29
    Internationalized normalized ratio (INR) 1.03 ± 0.08 1.08 ± 0.09 1.02 ± 0.07 0.02
    Platelets (1000 cells/mcL) 302.4 ± 72.1 306.8 ± 84.9 301.4 ± 69.4 0.83
  Fasting lipid profile:
    Triglycerides (mg/dL) 136.3 ± 81.3 106.4 ± 47.2 143.1 ± 86.0 0.05
    Cholesterol, total (mg/dL) 161.3 ± 31.9 145.5 ± 23.6 164.9 ± 32.6 0.02
    Cholesterol, HDL (mg/dL) 39.4 ± 8.8 39.7 ± 8.5 39.3 ± 8.9 0.82
    Cholesterol, LDL (mg/dL) 95.7 ± 24.8 86.4 ± 24.2 97.8 ± 24.6 0.20
  Fasting glucose and insulin:
    Glucose (mg/dL) 86.5 ± 19.2 84.2 ± 7.3 87.0 ± 21.0 0.82
    Insulin (mg/dL) 29.4 ± 20.3 29.5 ± 23.1 29.4 ± 19.9 0.76
    HbA1c (%) 5.4 ± 0.5 5.4 ± 0.3 5.4 ± 0.6 0.58
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ALT level (U/L)
Total*
(N=91)
Normal
(N=17)
Mildly
Elevated
(N=74) P†
    HOMA-IR 6.3 ± 4.5 6.0 ± 4.8 6.3 ± 4.4 0.69
Histologic characteristics, N (%):
  Steatosis grade: 0.02
    0 – 4% 9 (10%) 4 (24%) 5 (7%)
    5 – 33% (mild) 41 (45%) 9 (53%) 32 (43%)
    > 33% (moderate or severe) 41 (45%) 4 (24%) 37 (50%)
  Lobular inflammation, 20× mag: 0.52
    < 2 71 (78%) 12 (71%) 59 (80%)
    ≥ 2 20 (22%) 5 (29%) 15 (20%)
  Portal chronic inflammation: 0.73
    None 17 (19%) 4 (24%) 13 (18%)
    Mild/More than mild 74 (81%) 13 (76%) 61 (82%)
  Ballooning injury: 0.38
    None 65 (71%) 14 (82%) 51 (69%)
    Few/many 26 (29%) 3 (18%) 23 (31%)
  Acidophil bodies: 1.00
    Rare/absent 65 (71%) 12 (71%) 53 (72%)
    Many 26 (29%) 5 (29%) 21 (28%)
  Fibrosis stage: 0.002
    None (0) 49 (54%) 15 (88%) 34 (46%)
    Mild (1)
      Perisinusoidal, Zone 3 (1a)^ 6 (7%) 0 (0%) 6 (8%)
      Perisinusoidal, Zone 3, (1b)^ 1 (1%) 0 (0%) 1 (1%)
      Portal/periportal (1c) 23 (25%) 2 (12%) 21 (28%)
    Moderate (2)
      Perisinusoidal and portal, periportal 5 (5%) 0 (0%) 5 (7%)
    Severe (3 or 4)
      Bridging fibrosis or cirrhosis 7 (8%) 0 (0%) 7 (9%)
  Steatohepatitis diagnosis: 0.61
    NAFLD, not NASH 52 (57%) 12 (71%) 40 (54%)
    Suspicious/borderline Zone 3 (1a) 15 (16%) 2 (12%) 13 (18%)
    Suspicious/borderline Zone 1 (1b) 17 (19%) 3 (18%) 14 (19%)
    Definite 7 (8%) 0 (0%) 7 (9%)
  NAFLD Activity Score: 0.31
    0 – 3 60 (66%) 13 (76%) 47 (64%)
    4 – 8 31 (34%) 4 (24%) 27 (36%)
      Mean ± SD 3.1 ± 1.2 2.6 ± 1.3 3.2 ± 1.2 0.05
*All participants who were ages 5 through 18 at enrollment in with a centrally reviewed biopsy within 180 days of enrollment or blood draw for the
ALT measure and diagnosed with NAFLD by either the locally or centrally read biopsy were included in the study.
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No. missing values for a characteristic reported in parentheses by ALT group (0–25,26–50): Hispanic (0,1), Cholesterol: LDL (0,1,6), Insulin,
HOMA-IR (2,5), INR (0,1)
†
P values (2-sided) determined from either a Fisher exact test, a chi-square test or a Cochran-Armitage test for trend (for ordered categories) for
categorical variables or a Wilcoxon Rank sum test for continuous variables.
^1a fibrosis requires trichrome stain, 1b fibrosis can be visualized by HE stain.
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Table II
Demographic, Clinical and Histologic Characteristics of Pediatric Participants with NAFLD Comparing
Mildly Elevated and Elevated Levels of Alanine Aminotransferase (ALT)
ALT level (U/L)*
Mildly
Elevated
(N=74)
Elevated
(N=392) P
†
Demographics:
  Male, N (%) 47 (64%) 293 (75%) 0.05
  Age at enrollment (years), mean ± SD [range] 12.6 ± 2.5 [7, 18] 12.6 ± 2.7 [5, 18] 0.84
  Caucasian, N (%) 54 (73%) 304 (78%) 0.37
  Hispanic, N (%) 45 (62%) 246 (63%) 0.86
Anthropometric:
  Tanner stage 1, N (%) 17 (23%) 131 (33%) 0.37
    Stage 2–3 46 (62%) 192 (49%)
    Stage 4–5 11 (15%) 69 (18%)
  Body Mass Index (Z-score), N (%): 0.26
    < 2.0 (overweight or less) 19 (26%) 82 (21%)
    2.0 – (moderately obese) 35 (47%) 182 (46%)
    2.5 or more (severely obese) 20 (27%) 128 (33%)
Co-morbidities (diagnosis and/or treatment):
  Diabetes, N (%) 8 (11%) 17 (4%) 0.04
  Hyperlipidemia, N (%) 7 (9%) 27 (7%) 0.43
  High Blood Pressure, N (%) 5 (7%) 27 (7%) 0.97
Laboratory values, mean ± SD:
  Liver panel and platelets:
    ALT (U/L) 37.4 ± 6.8 123.1 ± 87.6 <0.00001
    AST (U/L) 31.6 ± 7.8 71.9 ± 48.4 <0.00001
    GGT (U/L) 29.8 ± 20.2 50.7 ± 36.2 <0.00001
    Creatinine (mg/dL) 0.58 ± 0.14 0.63 ± 0.58 0.89
    Bilirubin, direct (mg/dL) 0.09 ± 0.05 0.09 ± 0.07 0.54
    Albumin (g/dL) 4.4 ± 0.4 4.5 ± 0.4 0.32
    Internationalized normalized ratio (INR) 1.02 ± 0.07 1.04 ± 0.07 0.12
    Platelets (1000 cells/mcL) 301.4 ± 69.4 292.6 ± 70.8 0.31
  Fasting lipid profile:
    Triglycerides (mg/dL) 143.1 ± 86.0 147.7 ± 87.0 0.73
    Cholesterol, total (mg/dL) 164.9 ± 32.6 171.0 ± 39.2 0.24
    Cholesterol, HDL (mg/dL) 39.3 ± 8.9 38.5 ± 9.7 0.41
    Cholesterol, LDL (mg/dL) 97.8 ± 24.6 103.2 ± 30.5 0.16
  Fasting glucose and insulin:
    Glucose (mg/dL) 87.0 ± 21.0 88.5 ± 16.6 0.03
    Insulin (mg/dL) 29.4 ± 19.9 35.4 ± 37.6 0.27
    HbA1c (%) 5.4 ± 0.6 5.4 ± 0.7 0.47
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ALT level (U/L)*
Mildly
Elevated
(N=74)
Elevated
(N=392) P
†
    HOMA-IR 6.3 ± 4.4 7.9 ± 9.1 0.19
Histologic characteristics, N (%):
  Steatosis grade: <0.0001
    0 – 4% 5 (7%) 11 (3%)
    5 – 33% (mild) 32 (43%) 89 (23%)
    > 33% (moderate or severe) 37 (50%) 292 (74%)
  Lobular inflammation, 20× mag: <0.0001
    < 2 59 (80%) 203 (52%)
    ≥ 2 15 (20%) 189 (48%)
  Portal chronic inflammation: 0.003
    None 13 (18%) 27 (7%)
    Mild/More than mild 61 (82%) 365 (93%)
  Ballooning injury: 0.006
    None 51 (69%) 202 (52%)
    Few/many 23 (31%) 190 (48%)
  Acidophil bodies: 0.003
    Rare/absent 53 (72%) 206 (53%)
    Many 21 (28%) 186 (47%)
  Fibrosis stage: 0.001
    None (0) 34 (46%) 106 (27%)
    Mild: (1)
      Perisinusoidal, Zone 3, (1a)^ 6 (8%) 27 (7%)
      Perisinusoidal, Zone 3, (1b)^ 1 (1%) 17 (4%)
      Portal, periportal (1c) 21 (28%) 113 (29%)
    Moderate (2):
      Perisinusoidal and portal/periportal 5 (7%) 70 (18%)
    Severe (3 or 4)
      Bridging or Cirrhosis (3, 4) 7 (9%) 57 (15%)
  Steatohepatitis diagnosis: <0.0001
    NAFLD, not NASH 40 (54%) 89 (23%)
    Suspicious/borderline Zone 3 (1a) 13 (18%) 72 (18%)
    Suspicious/borderline Zone 1 (1b) 14 (19%) 115 (29%)
    Definite 7 (9%) 116 (30%)
  NAFLD Activity Score: <0.0001
    0 – 3 47 (64%) 111 (28%)
    4 – 8 27 (36%) 281 (72%)
      Mean ± SD 3.2 ± 1.2 4.4 ± 1.5 <0.00001
*
Mildly Elevated is defined as ALT 26–50 U/L for boys and 23–44 U/L for girls; Elevated ALT is defined as ALT > 50 U/L for boys and > 44 U/L
for girls
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No. missing values for a characteristic reported in parentheses by ALT group (26–50, >50): Caucasian (0,1), Hispanic (1,0), Triglycerides (0,4),
Cholesterol: total (0,3), HDL (0,4), LDL (1,6), Glucose (0,2), Insulin, HOMA-IR (5,1), HbA1c (0,5), Bilirubin (0,1), INR (1,1), Fibrosis (0,2)
†
P values (2-sided) determined from either a Fisher exact test, a chi-square test or a Cochran-Armitage test for trend (for ordered categories) for
categorical variables or a Wilcoxon Rank sum test for continuous variables.
^1a fibrosis requires trichrome stain, 1b fibrosis can be visualized by HE stain.
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